WINNIPEG, MB, June 20, 2022 /PRNewswire/ – (June 20, 2022) Medicine Inc. (“Medicine“or the”Company“) (TSXV: MPH) (OTC: MCUJF), a company focused on the development and commercialization of pharmaceutical and healthcare products for patients and prescribers in United States market, is pleased to announce that the following persons were elected directors at its annual general meeting of shareholders held on June 162022: dr. Albert Friesen, Gerald McDole, Brent Fawkesdr. Arnold Naimark, Pierre Quick and James Kinley. In addition, the shareholders reappointed Ernst & Young LLP, Chartered Accountants, as the Company’s auditor.

On behalf of the board and management, Dr. Albert D. FriesenCEO and Chairman of the Board, said: “We would like to thank Manon Harvey for her mandate as administrator and are happy to welcome James Kinley as the newest addition to the board.”

About Medicine Inc.
Medicure is a pharmaceutical company specializing in the development and commercialization of therapies for the US cardiovascular market. The current objective of the company is the marketing and distribution of AGGRASTAT® (tirofiban hydrochloride) injection and ZYPITAMAG® (pitavastatin) tablets in United Stateswhere they are sold through the Company’s US subsidiary, Medicure Pharma Inc. Medicure also operates Marley Drug, Inc. (“Marley Drug”), a pharmacy located in North Carolina which offers an extended drug supply program serving all 50 states, washington d.c. and Porto Rico. Marley’s drug® is committed to improving the health status of its patients and the communities they serve while reducing overall health care costs for employers and other consumers of health care. For more information, visit www.marleydrug.com. To learn more about the Extended Generic Drug Supply Program, call 800.286.6781 or email [email protected]. For more information on Medicine, please visit www.medicure.com. For more information on AGGRASTAT®refer to the full Prescribing Information. For more information on ZYPITAMAG®refer to the full Prescribing information.

To be added to the Medicure mailing list, please visit:
http://medicure.mediaroom.com/alerts

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking information: statements contained in this press release that are not statements of historical fact, including, without limitation, statements containing the words “believes”, “may”, “plans”, “will” , “estimates”, “continues”, “anticipates”, “intends”, “expects” and similar expressions, may constitute “forward-looking information” within the meaning of applicable Canadian and United States federal laws on securities (such forward-looking information and forward-looking statements are hereinafter collectively referred to as “forward-looking statements”). Forward-looking statements include estimates, analyzes and opinions of the Company’s management made in light of its experience and perception of trends, current conditions and expected developments, as well as other factors that the Company believes relevant and reasonable under the conditions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are beyond the Company’s ability to predict or control and that may cause actual results, events or developments to differ materially from the results, future events or developments expressed or implied by such forward-looking statements and, as such, readers are cautioned not to place undue reliance on any forward-looking statements. These risk factors include, among others, future revenues of the Company’s products, expected results, including future revenues of P5P, the likelihood of receiving a priority review voucher from the United States Food and Drug Administration , expected future revenue growth, stage of development, additional capital requirements, risks associated with the completion and timing of clinical trials and obtaining regulatory approval to commercialize the Company’s products, the ability to protect its intellectual property, dependence on collaborative partners, changes in government regulations or regulatory approval processes and rapid technological change in the industry. These statements are based on a number of assumptions which may prove to be incorrect, including, but not limited to, assumptions regarding: general business and economic conditions; the impact of fluctuations in the Canadian dollar against the US dollar and other foreign exchange rates on the Company’s revenues, costs and results; the timing of receipt of regulatory and governmental approvals for the Company’s research and development projects; the availability of financing for the Company’s commercial operations and/or research and development projects, or the availability of financing on reasonable terms; results of current and future clinical trials; uncertainties associated with acceptance and demand for new products and market competition. The above list of material factors and assumptions is not exhaustive. The Company undertakes no obligation to publicly update or otherwise revise any forward-looking statements or the foregoing list of factors, except as required by applicable law. Additional discussion of risks and uncertainties relating to the Company and its business can be found in the Company’s other filings with applicable Canadian securities regulators or the United States Securities and Exchange Commission, and in the “Risk Factors” section of his Form 20F for the year ended December 31, 2021.

AGGRASTAT® (tirofiban hydrochloride) injection and ZYPITAMAG® (pitavastatin) tablets are registered trademarks of Medicure International Inc. Marley Drug® is a registered trademark of Medicure Pharma Inc.

Show original content:https://www.prnewswire.com/news-releases/medicure-announces-results-of-2022-agm-301571342.html

SOURCE Medicine Inc.